TIDMAREC

RNS Number : 1925L

Arecor Therapeutics PLC

09 September 2021

Arecor Therapeutics plc

("Arecor" or the "Group")

FDA CLEARANCE OF Investigational New Drug application for AT247, AN ULTRA-RAPID INSULIN FOR THE TREATMENT OF DIABETES

Cambridge, UK, 9 September 2021. Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical group advancing today's therapies to enable healthier lives, today announces U.S. Food and Drug Administration (FDA) clearance of the Group's Investigational New Drug (IND) application for AT247, the Group's proprietary wholly owned ultra-rapid insulin for the treatment of diabetes.

The IND supports a Phase I clinical trial in the US in approximately 24 participants with type I diabetes, to further explore the clinical benefits of AT247. The trial is a double blind, randomised, three way crossover study comparing the pharmacokinetics (PK) and pharmacodynamics (PD) of AT247 with Novo Nordisk's NovoRapid(R) and Fiasp(R), two market-leading rapid acting insulin treatments. It will be the first trial to investigate the product's potential when delivered by continuous subcutaneous infusion via insulin pump over a period of 3 days and follows a previous successful first-in-man clinical study.

AT247, a novel formulation of insulin, aims to accelerate insulin absorption, post injection, to enable more effective management of blood glucose levels for people living with diabetes. AT247 has the potential to significantly improve post prandial glucose control so avoiding episodes of both hypo and hyperglycemia. In a recently published European Phase I clinical study in Type I diabetic patients, AT247 exhibited an earlier insulin appearance, exposure, and offset, with corresponding enhanced early glucose-lowering effect compared with NovoRapid(R) and Fiasp(R). This Phase I clinical data suggests that AT247 may also facilitate a fully closed loop artificial pancreas, a potentially life changing treatment option for people living with diabetes. This trial is expected to complete in 2022.

Sarah Howell, Chief Executive Officer of Arecor, said: " FDA clearance of the IND for AT247 marks an important milestone for this product, which has been enabled with our proprietary formulation technology platform, Arestat(TM). We look forward to initiating the next clinical study, which will be our first study in the US, and has been designed to further demonstrate the superiority of AT247 compared to current market leaders. With c. 463 million people living with diabetes world-wide, of which approximately 56 million are insulin users, the management of blood glucose control remains a serious issue. We believe that AT247 has the potential to help patients lead healthier lives."

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014 (MAR)

-ENDS-

For more information, please contact:

 
 Arecor Therapeutics plc                  www.arecor.com 
 Dr Sarah Howell, Chief Executive         Tel: +44 (0) 1223 426060 
  Officer                                  Email: info@arecor.com 
 
 Susan Lowther, Chief Financial Officer   Tel: +44 (0) 1223 426060 
                                           Email: info@arecor.com 
 
 Mo Noonan, Communications                Tel: +44 (0) 7876 444977 
                                           Email: mo.noonan@arecor.com 
 
 Panmure Gordon (UK) Limited (NOMAD       Tel: +44 (0) 20 7886 2500 
  and Broker) 
  Freddy Crossley, Emma Earl (Corporate 
  Finance) 
  Rupert Dearden (Corporate Broking) 
 
 Consilium Strategic Communications 
 Chris Gardner, David Daley, Angela       Tel: +44 (0) 20 3709 5700 
  Gray                                     Email: arecor@consilium-comms.com

Notes to Editors

About Arecor

Arecor Therapeutics plc is a globally focused biopharmaceutical group transforming patient care by bringing innovative medicines to market through the enhancement of existing therapeutic products. By applying our innovative proprietary formulation technology platform, Arestat(TM) , we are developing an internal portfolio of proprietary products in diabetes and other indications, as well as working with leading pharmaceutical and biotechnology companies to deliver enhanced formulations of their therapeutic products. The Arestat (TM) platform is supported by an extensive patent portfolio .

For further details please see our website, www.arecor.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

MSCLPMBTMTBMTTB

(END) Dow Jones Newswires

September 09, 2021 02:00 ET (06:00 GMT)

Arecor Therapeutics (LSE:AREC)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Arecor Therapeutics Charts.
Arecor Therapeutics (LSE:AREC)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Arecor Therapeutics Charts.